Related Experiment Video
Updated: Mar 17, 2026
07:16
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
14.3K
Identification of Positive Allosteric Modulators of Glycine Receptors from a High-Throughput Screen Using a
Clara Stead1, Adam Brown1, Cathryn Adams1
11 Neusentis (Pfizer Ltd.), Granta Park, Great Abington, Cambridgeshire, UK.
Journal of Biomolecular Screening
|July 15, 2016
Summary
Researchers identified novel small-molecule positive allosteric modulators (PAMs) for Glycine receptor 3 (GlyRα3). These GlyRα3 PAMs show high efficacy and selectivity, offering potential as new pain therapeutics and research tools.
Area of Science:
- Neuroscience
- Pharmacology
- Molecular Biology
Background:
- Glycine receptor 3 (GlyRα3) is crucial for inhibitory neurotransmission and pain signaling.
- Developing GlyRα3 positive allosteric modulators (PAMs) is a promising analgesic strategy.
- Lack of selective PAMs has hindered GlyRα3 research and therapeutic development.
Purpose of the Study:
- To develop and characterize novel, selective GlyRα3 PAMs.
- To identify tool compounds for studying GlyRα3 function.
- To establish a foundation for new analgesic drug discovery.
Main Methods:
- Established in vitro assays including high-throughput membrane potential screening and IonFlux HT electrophysiology.
- Conducted a primary screening campaign to identify GlyR PAMs.
- Performed functional characterization of hit compounds.
Main Results:
- Identified small-molecule GlyR PAMs with high efficacy.
- Demonstrated selectivity of identified PAMs over GABAA receptors.
- Reported structures of identified GlyR PAMs.
Conclusions:
- Developed effective pharmacological tools for GlyRα3 research.
- Identified potent and selective GlyRα3 PAMs with therapeutic potential.
- These findings represent a significant advancement in targeting GlyRα3 for pain management.
